Who protects my safety in a clinical trial?
Several groups do, and no single one of them acts alone. Your safety rests on informed consent, on review of the trial plan before anyone joins, and on monitoring that continues while the trial runs.
Two reviews before anyone enrolls
Every clinical trial funded by the federal government must be reviewed by scientists in the relevant field before people can enroll. This checks that the trial rests on sound science.
That review is not required for trials paid for by drug companies and other private sponsors. Many seek expert advice anyway, but it is a choice, not a rule. If you are looking at an industry trial, it is fair to ask who reviewed the science.
The second review comes from an institutional review board, or IRB. The IRB looks at the trial protocol, which is the written plan, before the trial can accept a single patient. It checks that the study is well designed, legal, and ethical, that it does not carry needless risk, and that it includes a safety plan.
What an IRB must be made of
An IRB is not just a group of the hospital's own doctors. Federal rules at 45 CFR 46.107 require at least five members. At least one must have primary concerns in a scientific area, and at least one in a nonscientific area. At least one member must not be affiliated with the institution and must not be an immediate family member of someone who is. Any member with a conflicting interest is barred from reviewing that project, other than to answer questions.
Boards often add nurses, social workers, chaplains, and patient advocates.
IRBs also review trials again after they open. NCI states plainly that IRBs review trial protocols yearly. The regulation is a little more layered. Under 45 CFR 46.109(e), continuing review of research needing a full board meeting happens at intervals set by the degree of risk, and not less than once a year. But section 46.109(f) lists cases where continuing review is not required, such as studies eligible for a faster review track, or a study that has moved on to data analysis alone. For the treatment trials most people with cancer join, the yearly review is the norm.
Who watches while the trial runs
Some trials, especially phase 3 trials, use a data and safety monitoring board, or DSMB. This is an independent group of doctors, statisticians, and other research experts who are not running the trial. They review both safety and how well the treatment is working, and they confirm the data are complete.
Two federal offices sit above all of this. The Office for Human Research Protections enforces the Common Rule, which sets standards for consent, for how IRBs are formed, and for research involving children, prisoners, and other groups at risk of pressure. The Food and Drug Administration protects the integrity of trial data and can remove researchers who break safety rules.
Why a trial gets stopped early
Most trials run start to finish, but an IRB or a DSMB can halt one. A trial may stop because participants are having unexpected, severe side effects. It may stop because the new treatment is clearly working, so others can get it sooner. It may stop because the treatment is clearly not working and people should not stay on it. Or it may stop because too few people enrolled, or another study already answered the question.
Consent is your own layer in this system, and it does not end at signing. Our guide to your safety in a clinical trial covers the monitoring in more depth, and the piece on informed consent in clinical trials walks through the form itself.
Sources
Want the full picture? Read our complete explanation: How Is Your Safety Protected in a Clinical Trial?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.